Patrick Vigneault, Ph.D.

Patrick Vigneault is an associate principal scientist in the Precision Cardiology Laboratory (PCL) of the Broad Institute and Bayer, a joint venture between the Broad Institute and Bayer, where he works at the interface of molecular cardiology and precision medicine. He is a drug hunter at heart. His mission is to decode the mechanisms driving heart disease progression and translate those insights into novel, druggable targets that can reshape how cardiovascular disease is treated.

Vigneault is driven by a singular goal: to leverage deep expertise in cardiovascular biology to identify and validate the next generation of precision therapeutics — turning fundamental mechanistic discoveries into breakthrough medicines that change patients' lives.

His scientific foundation was built at the Université de Montréal, where he earned his Ph.D. under the mentorship of Dr. Stanley Nattel, investigating the functional role of calcium-activated potassium channels in undifferentiated cardiac-derived stem cells — work aimed at uncovering the mechanisms that govern their regenerative capacity. He went on to complete a joint postdoctoral fellowship spanning Amgen and the University of Southern California, bridging academic mechanistic research with industry drug discovery practice.

Across every stage of his career, Vigneault has followed a consistent thread: pursue the mechanism, find the target, and pressure-test it toward a medicine — the core discipline of a drug hunter in cardiovascular disease.